Detalhe da pesquisa
1.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
N Engl J Med
; 390(19): 1745-1755, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38749032
2.
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Circulation
; 147(13): 1026-1038, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802876
3.
Effectiveness and safety of anticoagulants among patients with venous thromboembolism and common cancers or cancers with high venous thromboembolism risk.
Future Oncol
; 20(9): 521-532, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197229
4.
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
J Thromb Thrombolysis
; 2024 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735015
5.
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.
Eur Heart J
; 44(14): 1231-1244, 2023 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648242
6.
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Circulation
; 145(19): 1471-1479, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389229
7.
Bleeding related hospitalizations and mortality in England 2014-2019.
J Thromb Thrombolysis
; 56(2): 233-240, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338712
8.
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
J Thromb Thrombolysis
; 55(2): 211-221, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36566304
9.
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
N Engl J Med
; 380(14): 1326-1335, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30730782
10.
Recommendations for Research Assessing Outcomes for Patients With Anticoagulant-Related Intracerebral Bleeds.
Stroke
; 52(4): 1520-1526, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618554
11.
The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis.
Circulation
; 149(16): 1315-1318, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620086
12.
Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients.
Br J Haematol
; 189(3): 524-533, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31997309
13.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
N Engl J Med
; 376(13): 1211-1222, 2017 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28316279
14.
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
J Thromb Thrombolysis
; 49(2): 214-219, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31493287
15.
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
N Engl J Med
; 375(6): 534-44, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27232649
16.
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
N Engl J Med
; 375(12): 1131-41, 2016 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573206
17.
Anticoagulant selection for patients with VTE-Evidence from a systematic literature review of network meta-analyses.
Pharmacol Res
; 143: 166-177, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30905806
18.
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
Am J Hematol
; 94(1): 21-28, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30252149
19.
Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.
Qual Life Res
; 28(5): 1155-1177, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30607785
20.
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Circulation
; 135(7): 648-655, 2017 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27881569